

IN THE CLAIMS

1-37. (canceled)

38. (previously presented) A once-a-day composition comprising:
- (a) an immediate release component comprising bupropion or a pharmaceutically acceptable salt thereof;
 - (b) a first pellet comprising an enteric release component comprising bupropion or a pharmaceutically acceptable salt thereof and a pH dependent coating polymer; and
 - (c) a second pellet comprising a sustained release component comprising bupropion or a pharmaceutically acceptable salt thereof and a water insoluble coating polymer,

wherein said composition contains 75 to 450 mg of bupropion or a pharmaceutically acceptable salt thereof and provides an in vivo plasma profile selected from:

- (a) a mean C_{\max} of at least 50.0 ng/ml;
 - (b) a mean $AUC_{0-\infty}$ of greater than approximately 500.0 ng·hr/ml; and
 - (c) a mean T_{\max} of between approximately 5.0 hours and 8.5 hours based upon a single dose administration of a composition containing 150 mg of bupropion or a pharmaceutically acceptable salt.
39. (previously presented) The composition of claim 38 wherein the immediate release component is a powder, granule or uncoated active pellet.
40. (previously presented) The composition of claim 38 wherein said first pellet comprises a core containing the bupropion or pharmaceutically acceptable salt thereof and the pH dependent coating polymer is applied to the core.
41. (previously presented) The composition of claim 38 wherein said second pellet comprises a core containing the bupropion or pharmaceutically acceptable salt thereof and the water insoluble coating polymer is applied to the core.
42. (previously presented) The composition of claim 38 wherein said pH dependent coating polymer is selected from the group consisting of shellac, methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and mixtures thereof.
43. (previously presented) The composition of claim 38 wherein said water insoluble coating polymer is selected from the group consisting of ethyl cellulose, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate and mono-, di- and tri-cellulose arylates.
44. (previously presented) The composition of claim 38 wherein the composition is a tablet.
45. (previously presented) The composition of claim 38 wherein the composition is a capsule.

46. (previously presented) The composition of claim 38 wherein the sustain release component further comprises a methacrylic acid copolymer.
47. (previously presented) The composition of claim 38 wherein the mean C_{\max} is less than 90 ng/ml.
48. (previously presented) The composition of claim 47 wherein the mean C_{\max} is less than 80 ng/ml.
49. (previously presented) The composition of claim 48 wherein the mean C_{\max} is less than 70 ng/ml.
50. (previously presented) The composition of claim 38 wherein the mean T_{\max} is 5.1 hours to 8.1 hours.